3-(4-amino-3-nitrophenoxy)propyl chloride | 193205-28-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-amino-3-nitrophenoxy)propyl chloride
• 英文别名: 4-(3-Chloropropoxy)-2-nitroaniline
• CAS: 193205-28-6
• 化学式: C₉H₁₁ClN₂O₃
• 分子量: 230.651
• InChiKey: XGUSOWSGEDWPQQ-UHFFFAOYSA-N

物化性质

• 沸点：
  419.3±30.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-苄基哌啶 、 3-(4-amino-3-nitrophenoxy)propyl chloride 在 sodium iodide 作用下， 以 甲苯 为溶剂， 生成 1-[3-(4-Amino-3-nitrophenoxy)propyl]-4-benzylpiperidine
  参考文献：
  名称：

  US6124323

  摘要：

  公开号：
• 作为产物：
  描述：

  N-[4-(3-chloropropoxy)-2-nitrophenyl]acetamide 在 盐酸 作用下， 以93%的产率得到3-(4-amino-3-nitrophenoxy)propyl chloride
  参考文献：
  名称：

  Two new phenylpiperazines with atypical antipsychotic potential

  摘要：

  Two new series of substituted arylpiperazines with heterocyclic 3-propoxy-benzimidazole or 3-propoxy-benzimidazole-2-thione groups were synthesized and their in vitro binding affinities for the D,, 5-HT1A, 5-HT2A, and alpha-adrenergic receptors determined. Among them, only two compounds with phenyl aryl-constituent (8a and 9a) showed 5-HT2A/D-2 pK(i) binding ratios proposed for atypical neuroleptics. As to their behavioral screening on rodents, both compounds exhibited a non-cataleptic action in rats and antagonized D-amphetamine-induced hyperlocomotion in mice, suggesting their possible atypical antipsychotic potency. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.08.066

文献信息

• Subtype-selective NMDA receptor ligands and the use thereof
  申请人：Warner-Lambert Co.

  公开号：US06218404B1

  公开（公告）日：2001-04-17

  The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neuro-degenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

  该发明涉及亚型选择性NMDA受体配体及其用于治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失，以及治疗包括阿尔茨海默病、肌萎缩性侧索硬化、亨廷顿病和唐氏综合征在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑、精神病、抽搐、氨基糖苷类抗生素引起的听力损失、偏头痛、慢性疼痛、帕金森病、青光眼、巨细胞病毒性视网膜炎、尿失禁、阿片类药物耐受性或戒断症状，并诱导麻醉，以及增强认知能力。
• EP0869792A4
  申请人：——

  公开号：EP0869792A4

  公开（公告）日：1999-09-22
• 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0869792A2

  公开（公告）日：1998-10-14
• US6124323A
  申请人：——

  公开号：US6124323A

  公开（公告）日：2000-09-26
• US6218404B1
  申请人：——

  公开号：US6218404B1

  公开（公告）日：2001-04-17